AI Summary
✦ ClarthaValuation Metrics
Trading 10.8% below historical median. Valuation is stable — currently in the strongly undervalued zone (z-score: -0.59). Confidence: 86%.
Live forward EPS implies next-12-month EPS of ₹27.90. Applying the stock's normalized valuation corridor produces a fair range of ₹528.98 to ₹672.95, with base value near ₹622.45 (+47.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹27.90
Forward P/E
15.2x
Base Fair Value
₹622.45
Fair Range
₹528.98 - ₹672.95
Upside To Base
+47.3%
Estimate Source
Live forward EPS
Growth Estimate
-7.1%
5Y Average
21.60
Current
19.89
Overvalued
24.12
Undervalued
18.96
5Y Average
1.54
Current
1.44
Overvalued
1.77
Undervalued
1.31
5Y Average
2.62
Current
2.49
Overvalued
3.01
Undervalued
2.23
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.0x Undervalued | -57% vs avg | +43.4% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 48.8x Undervalued | -25% vs avg | -14.9% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.8x Undervalued | -33% vs avg | +45.4% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Undervalued | -33% vs avg | -25.8% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 162.0x Premium | +148% vs avg | -52.7% |
AARTI DRUGS LTD. trades at a discount (20.2x vs peer avg 65.3x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include ALIVUS LIFE SCIENCES LTD, CONCORD BIOTECH LIMITED, AKUMS DRUGS AND PHARMA L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹627 CrJun 2026Latest net profit
₹51 CrJun 2026Latest EPS
₹5.57Jun 2026Net margin
15.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 592 | 578 | 538 | 560 | 493 | 543 | 515 | 623 | 521 | 579 | 529 | 632 | 627 |
| Expenses + | 520 | 512 | 478 | 490 | 439 | 484 | 454 | 534 | 457 | 504 | 486 | 552 | 536 |
| Operating Profit | 72 | 65 | 60 | 69 | 54 | 60 | 60 | 89 | 64 | 75 | 42 | 79 | 92 |
| OPM % | 12% | 11% | 11% | 12% | 11% | 11% | 12% | 14% | 12% | 13% | 8% | 13% | 15% |
| Other Income + | 1 | 1 | 2 | 1 | 0 | 0 | 11 | 2 | 0 | 0 | 1 | 1 | -2 |
| Interest | 8 | 8 | 7 | 8 | 7 | 7 | 8 | 7 | 7 | 6 | 7 | 7 | 7 |
| Depreciation | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 | 15 | 15 | 15 |
| Profit before tax | 53 | 47 | 43 | 50 | 35 | 41 | 52 | 71 | 45 | 56 | 22 | 59 | 68 |
| Tax % | 25% | 26% | 26% | 27% | 23% | 26% | 26% | 13% | -7% | 25% | -56% | 23% | 25% |
| Net Profit + | 40 | 35 | 32 | 36 | 27 | 30 | 39 | 61 | 49 | 42 | 34 | 45 | 51 |
| EPS in Rs | 4.27 | 3.76 | 3.44 | 3.93 | 2.93 | 3.33 | 4.22 | 6.74 | 5.33 | 4.58 | 3.71 | 4.93 | 5.57 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome